bovnews6h
Briacell Therapeutics Corp (BCTX) Stock: Unveiling Its Hidden Strengths
Briacell Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.03%. The profit margin, also known as the revenue ratio or gross profit ...
Promising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell Therapeutics
BriaCell Therapeutics (BCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...
T-Net4h
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board ...
Cure Today12d
First Patient Dosed in Study Assessing Immunotherapy in Metastatic Breast Cancer
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
BriaCell Therapeutics’ (BCTX) Buy Rating Reiterated at HC Wainwright
BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga ...
Nasdaq10d
BriaCell says DSMB recommends continuation of Phase 3 study in MBC
BriaCell (BCTX) Therapeutics announces that the Data Safety Monitoring Board has completed its first review of safety events in patients enrolled in BriaCell’s pivotal randomized Phase 3 study ...
Yahoo Finance21d
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) a clinical-stage biotech company that develops novel ...
ETF Daily News8d
BriaCell Therapeutics (NASDAQ:BCTXW) Trading Up 12.2% – Here’s Why
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in ...
Morningstar16d
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast ...